AUS
NZ
UK
CA
USA
IND
Oxford Nanopore Technologies PLC (LON:ONT) has launched a major initiative in collaboration with Singapore's National Precision Medicine programme, led by Precision Health Research. This landmark project will see Oxford Nanopore sequencing 10,000 genomes to build a comprehensive catalogue of structural variants. This catalogue aims to aid scientists in understanding human genetic diversity and diseases.
Project Details and Financial Impact
The Oxford-based firm, renowned for its advancements in DNA and RNA sequencing technologies, anticipates that the project will last approximately one year, having started in mid-2024. Despite the scale of this undertaking, there will be no alterations to the company's financial guidance for 2024 and the medium term.
CEO Comments on the Collaboration
Gordon Sanghera, the CEO, expressed enthusiasm about the partnership. It was noted that the collaboration with Singapore's National Precision Medicine programme is expected to create one of the most extensive and inclusive reference genome datasets globally. Additionally, it was highlighted that this project not only reinforces their commitment to precision healthcare but also strategically positions Singapore as a pivotal hub for genomics in the Asia Pacific region, which is anticipated to foster significant advancements in medical research and healthcare outcomes.
